




# Antiproliferative and Anticancer Activity of Chrysin on Human A549 Lung Cancer Cell Lines; Possible Clinical Application

Armin Asghari<sup>1</sup>, Akram Firouzihamdi<sup>2</sup>, Mehdi Dadashpour <sup>1,3,4,\*</sup>

<sup>1</sup> Department of Medical Biotechnology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran

<sup>2</sup> Tabriz University of Medical Sciences, Tabriz, Iran

<sup>3</sup> Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran

<sup>4</sup> Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran

\*Corresponding Author: Department of Medical Biotechnology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran. Email: dadashpouremehdi400@gmail.com

Received: 2 October, 2024; Revised: 19 October, 2024; Accepted: 29 October, 2024

## Abstract

The current study aimed to assess the anticancer properties of Chrysin (Chr) as a potential therapeutic option for cancer. For this purpose, we analyzed both its toxic effects on the cells and the levels of genes related to apoptosis following treatment with Chr. The effect of Chr on cell proliferation and the expression levels of apoptosis-related genes in the A549 lung cell line was evaluated using the MTT assay and qPCR, respectively. The findings from the cytotoxicity test revealed that the  $IC_{50}$  of Chr for A549 lung cancer cells was 20  $\mu$ M. This result indicates that Chr exhibits significant cytotoxic effects at this concentration, underscoring its potential as a powerful anticancer agent. Furthermore, the real-time PCR analysis showed significant changes in gene expression after treatment with Chr. Specifically, Chr was found to decrease the expression of human telomerase reverse transcriptase (hTERT) and Bcl2, both associated with cell growth and survival. Conversely, Chr increased the expression of Bax, a gene that promotes apoptosis. These molecular changes suggest that Chr may induce apoptosis in A549 lung cancer cells by altering the balance between anti-apoptotic and pro-apoptotic factors. In conclusion, the findings from this study indicate that Chr effectively inhibits the growth of A549 lung cancer cells through its cytotoxic properties and the regulation of apoptosis-related gene expression. This property positions Chr as a promising candidate for further investigation and development in cancer treatment strategies, and additional studies are necessary to understand its mechanisms of action and potential therapeutic benefits.

**Keywords:** Chrysin, Anticancer Activity, A549 Lung Cancer Cell Line, Apoptosis

## 1. Background

Lung cancer is one of the leading causes of cancer morbidity and mortality worldwide, with its epidemiology marked by a higher incidence in smokers and individuals exposed to environmental carcinogens (1). The complexity of lung cancer, characterized by its heterogeneous nature and resistance to conventional therapies, necessitates the search for innovative therapeutic agents that can effectively target tumor cells while minimizing harmful effects. The etiology of lung cancer is multifactorial; while smoking is the strongest risk factor, it often acts synergistically with other factors. Smokers exposed to additional risk factors, such as radon and asbestos, face an increased risk of developing lung cancer (2). Not all smokers

develop lung cancer, highlighting the role of other factors, such as genetics, in influencing susceptibility. Although various treatment modalities, including surgery, radiation, chemotherapy, and immunotherapy, are available, the pursuit of safer and more effective approaches remains a priority. Traditional chemotherapy drugs are challenged by issues of resistance, systemic toxicity, and limited bioavailability (3). In advanced stages, novel treatment approaches, such as targeted therapies, are also available. The choice of treatment approach, whether used individually or in combination, depends on the patient's specific condition (4).

Researching new chemotherapy drugs to improve effectiveness is essential. Natural active compounds are regarded as a rich source of potential new anticancer

agents. Investigating the anticancer potential of these natural ingredients and their application in cancer drug development remains a key research focus (3, 5).

Chrysin (5,7-dihydroxyflavone) (Chr), a polyphenolic flavone commonly found in fruits, vegetables, and honey, is known for its roles in various biological pathways, including the prevention, delay, or reversal of cancer development (6). It possesses anti-inflammatory, antioxidant (7), immunomodulatory (8), and anticancer properties (9). Chrysin and its derivatives have shown significant apoptotic and anti-proliferative effects in human cancer cells from various origins, notably lung (10), breast (11), prostate (12), and colorectal cancers (13).

## 2. Objectives

In this study, we report the *in vitro* evaluation of Chr's anticancer properties. Additionally, Chr's capacity to inhibit cell growth and induce apoptosis was assessed in the A549 lung cancer cell line. This study underscores the potential of Chr to enhance the pharmacological efficacy of natural compounds, paving the way for their broader therapeutic application.

## 3. Methods

### 3.1. Materials

All reagents and materials were used as received. Human A549 lung cancer cells were obtained from the National Cell Bank of Iran (NCBI; Pasteur Institute, Tehran, Iran). Dimethyl sulfoxide (DMSO), Dulbecco's Modified Eagle's Medium (DMEM), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), Phosphate Buffered Saline (PBS), Fetal Bovine Serum (FBS), Penicillin-Streptomycin (Pen/Strep), and Trypsin-EDTA were sourced from Gibco.

### 3.2. Cell Culture

A549 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum, 1% penicillin, and 1% streptomycin. Cells were maintained under controlled culture conditions at 37°C with 5% CO<sub>2</sub> and 95% humidity.

### 3.3. *In Vitro* Cytotoxicity

Cell viability following Chr treatment was assessed using the MTT assay in A549 cancer cells as described by Khoshnavan et al. (14). A549 cancer cells were seeded in a 96-well plate at a density of  $1 \times 10^4$  cells per well and

incubated at 37°C for 24 hours. The cells were then treated with 100 µL of medium containing various concentrations of Chr (0, 5, 10, 20, and 40 µM) and incubated at 37°C for 24, 48, and 72 hours. Quantitative measurement of cell survival was conducted using the MTS kit, and the formazan salts formed were measured using an EL X 800 microplate absorbance reader (BioTek Instruments, Winooski, VT) at 570 nm.

### 3.4. Gene Expression of Apoptosis Related Genes

To study the expression of apoptosis-related genes in cancer cells, 24 hours after incubation with different concentrations of Chr, the culture medium was completely removed, and the cells were rinsed with PBS. The cells were then detached, and RNA was extracted using the RNX-Plus kit according to the manufacturer's instructions. The concentration and purity of the extracted RNA were determined using a spectrophotometer (Thermo Scientific™ NanoDrop™) and confirmed by agarose gel electrophoresis. Total RNA was reverse-transcribed into cDNA using the Prime Script RT reagent kit, following the manufacturer's protocol. Real-time PCR was conducted with SYBR Green PCR Master Mix (Ampliqon, Denmark) to analyze the expression levels of Bax, Bcl2, and human telomerase reverse transcriptase (hTERT). The expression of these target genes was compared to the housekeeping gene GAPDH using the comparative threshold cycle (Ct) method.


### 3.5. Statistical Analysis

The studies were conducted in triplicate, and the results are presented as the mean ± standard deviation. Data were analyzed for statistical significance using Student's *t*-test. A significance level of 0.05 was applied, with  $P < 0.05$  indicating significance (\*) and  $P > 0.05$  indicating non-significance (ns).

## 4. Results

### 4.1. Cytotoxicity Assay

The cytotoxic potential of Chr against malignant cells was assessed through an MTT assay conducted on A549 lung cancer cell lines. Following treatment durations of 24, 48, and 72 hours, Chr demonstrated dose-dependent inhibitory effects at concentrations ranging from 0 to 40 µM. The IC<sub>50</sub> value of Chr for A549 cell lines was determined to be  $20.51 \pm 1.27$  µM (Figure 1). These



**Figure 1.** The effect of various concentrations of Chrysin (Chr) on the A549 cancer cell viability was determined by MTT assay. Each condition includes data from at least three independent experiments. Values are expressed as mean  $\pm$  SEM. \* $P < 0.05$  compared to 20 and 40  $\mu$ M Chr.

findings suggest that Chr exhibits significant cytotoxicity against cancerous cell lines.

#### 4.2. Quantitative Real-time PCR Assay

The qPCR assay is a highly sensitive method used to quantify gene expression levels in various biological samples. Analysis of Bcl2 and hTERT gene expression in cancer cells revealed that Chr caused a significant decrease in the expression of these genes compared to the control group (Figure 2). In contrast, Bax gene expression in A549 human lung cancer cells significantly increased in the Chr-treated group compared to the control.

### 5. Discussion


The current report provides compelling evidence regarding the anticancer efficacy of Chr in A549 lung cancer cells. The study examined both the cytotoxic effects of Chr and its impact on the expression of key apoptotic genes, which play critical roles in the regulation of programmed cell death. The MTT assay determined an  $IC_{50}$  value of 20  $\mu$ M, indicating that Chr exhibits significant inhibitory effects on cell proliferation at this dose. This result aligns with previous studies suggesting Chr's potential to exert cytotoxic effects on various cancer cell lines.

Firouzi-Amandi et al. investigated the efficacy of Chr encapsulated in PLGA-PEG nanoparticles for macrophage modulation, demonstrating that this nanoformulated system possesses macrophage repolarization activities (4). In another study, the

anticancer activity of honey combined with Chr was assessed, showing a reduction in cell viability in a time- and dose-dependent manner in treated cancer cells (15). Among various cancer models, Chr's effects on preventing and controlling lung cancer growth have been widely evaluated both in vitro and in vivo (6, 9). In our previous studies, Chr combined with curcumin was shown to inhibit the proliferation, invasion, and metastasis of T47D breast cancer cells by downregulating hTERT gene expression (16).

Human telomerase reverse transcriptase is a critical enzyme that plays an essential role in cellular aging and cancer biology. As the catalytic subunit of the telomerase complex, hTERT is responsible for adding telomeric repeats to the ends of chromosomes, countering the progressive shortening of telomeres that occurs during DNA replication. This process is crucial for maintaining chromosomal stability, especially in stem cells and germ cells, which require extensive proliferative capacity (17).

Furthermore, the real-time PCR assessment provided insights into the molecular mechanisms underlying Chr's anticancer properties. Notably, the reduction in hTERT expression is significant, as hTERT is often associated with the "immortal" nature of cancer cells. By reducing hTERT levels, Chr may contribute to restoring normal cellular aging processes, thereby limiting the growth potential of A549 cells. Additionally, the observed decrease in Bcl2, a protein that inhibits apoptosis, alongside an increase in Bax, a protein that promotes apoptosis, suggests that Chr modulates apoptotic signaling pathways. This shift is crucial for



**Figure 2.** Inhibitory effects of Chrysin (Chr) on expression levels of A, human telomerase reverse transcriptase (hTERT); B, Bcl2; and C Bax in A549 cancer cells. \*  $P < 0.05$  and \*\*  $P < 0.01$  are the statistical difference between the combination form and individual drugs. Data represented are from three independent experiments.

enhancing apoptosis in cancer cells, facilitating their targeted elimination.

Previous research has provided strong evidence that an increase in the expression of key pro-apoptotic genes like Bax, along with a decrease in anti-apoptotic genes such as Bcl2, results in reduced survival rates for cancer cells (18, 19). Studies have shown that a 24-hour exposure period is sufficient to observe significant changes in cell viability and gene expression in response to various anticancer treatments. This duration allows for the evaluation of initial cellular responses to the treatment, including alterations in apoptotic pathways and gene regulation (20).

The findings from this study are significant, indicating that Chr may serve as a promising therapeutic option for lung cancer. Its ability to influence apoptosis-related gene expression and promote cell death underscores its potential as a candidate for further exploration in both preclinical and clinical research.

#### 5.1. Conclusions

In conclusion, this study highlights the significant anticancer efficacy of Chr against A549 lung cancer cells. The identified  $IC_{50}$  value of  $20 \mu M$  demonstrates that Chr effectively inhibits cell proliferation, underscoring its potential as a therapeutic agent. Moreover, the

modulation of apoptotic gene expression, particularly the upregulation of Bax and downregulation of hTERT and Bcl2 genes, suggests that Chr induces apoptosis in A549 lung cancer cells. These findings underscore the need for further research to elucidate the mechanisms underlying Chr's effects and its potential clinical applications. Overall, Chr appears to be a promising candidate for the development of innovative cancer treatments, especially for lung cancer. Future studies should explore its efficacy in vivo and examine potential synergistic interactions with existing therapies.

## Footnotes

**Authors' Contribution:** A. A. and A. F. A.: Investigation, methodology, data curation, preparation of original draft, writing-reviewing and editing; M. D.: Supervision, conceptualization, funding acquisition, reviewing and editing. All authors reviewed the manuscript.

**Conflict of Interests Statement:** We declare that one of our authors (Mehdi Dadashpour) is of the editorial board. The journal confirmed that the author with Col was excluded from all review processes.

**Data Availability:** The dataset presented in the study is available on request from the corresponding author during submission or after publication.

**Ethical Approval:** The ethical approval for this paper was obtained from Semnan University of Medical Sciences (IR.SEMUMS.REC.1400.336).

**Funding/Support:** This study was supported by grant from Cancer Cell Research Center (Grant NO: 2989).

## References

- Alagheband Y, Jafari-gharabaghlu D, Imani M, Mousazadeh H, Dadashpour M, Firouzi-Amandi A, et al. Design and fabrication of a dual-drug loaded nano-platform for synergistic anticancer and cytotoxicity effects on the expression of leptin in lung cancer treatment. *J Drug Deliver Sci Tech.* 2022;**73**. <https://doi.org/10.1016/j.jddst.2022.103389>.
- Amirsadat S, Jafari-Gharabaghlu D, Dadashpour M, Zarghami N. Potential Anti-Proliferative Effect of Nano-formulated Curcumin Through Modulating Micro RNA- 132, Cyclin D1, and hTERT Genes Expression in Breast Cancer Cell Lines. *J Cluster Sci.* 2023;**34**(5):2537-46. <https://doi.org/10.1007/s10876-023-02404-z>.
- Firouzi Amandi A, Jokar E, Eslami M, Dadashpour M, Rezaie M, Yazdani Y, et al. Enhanced anti-cancer effect of artemisinin- and curcumin-loaded niosomal nanoparticles against human colon cancer cells. *Med Oncol.* 2023;**40**(6):170. [PubMed ID: 37156929]. <https://doi.org/10.1007/s12032-023-02032-7>.
- Firouzi-Amandi A, Dadashpour M, Nouri M, Zarghami N, Serati-Nouri H, Jafari-Gharabaghlu D, et al. Chrysin-nanoencapsulated PLGA-PEG for macrophage repolarization: Possible application in tissue regeneration. *Biomed Pharmacother.* 2018;**105**:773-80. [PubMed ID: 29909345]. <https://doi.org/10.1016/j.biopha.2018.06.037>.
- Salmani Javan E, Lotfi F, Jafari-Gharabaghlu D, Mousazadeh H, Dadashpour M, Zarghami N. Development of a Magnetic Nanostructure for Co-delivery of Metformin and Silibinin on Growth of Lung Cancer Cells: Possible Action Through Leptin Gene and its Receptor Regulation. *Asian Pac J Cancer Prev.* 2022;**23**(2):519-27. [PubMed ID: 35225464]. [PubMed Central ID: PMC9272620]. <https://doi.org/10.31557/APJCP.2022.23.2.519>.
- Talebi M, Talebi M, Farkhondeh T, Simal-Gandara J, Kopustinskiene DM, Bernatoniene J, et al. Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin. *Cancer Cell Int.* 2021;**21**(1):214. [PubMed ID: 33858433]. [PubMed Central ID: PMC8050922]. <https://doi.org/10.1186/s12935-021-01906-y>.
- Orsolich N, Nemrava J, Jelec Z, Kukulj M, Odeh D, Jakopovic B, et al. Antioxidative and Anti-Inflammatory Activities of Chrysin and Naringenin in a Drug-Induced Bone Loss Model in Rats. *Int J Mol Sci.* 2022;**23**(5). [PubMed ID: 35270014]. [PubMed Central ID: PMC8911302]. <https://doi.org/10.3390/ijms23052872>.
- Zeinali M, Rezaee SA, Hosseinzadeh H. An overview on immunoregulatory and anti-inflammatory properties of chrysin and flavonoids substances. *Biomed Pharmacother.* 2017;**92**:998-1009. [PubMed ID: 28609844]. <https://doi.org/10.1016/j.biopha.2017.06.003>.
- Shahbaz M, Naeem H, Imran M, Ul Hassan H, Alsagaby SA, Al Abdulmonem W, et al. Chrysin a promising anticancer agent: recent perspectives. *Int J Food Propert.* 2023;**26**(1):2294-337. <https://doi.org/10.1080/10942912.2023.2246678>.
- Li D, Li L, Wang L, Li J, Zhang B. 7-Piperazine ethyl chrysin inhibits proliferation of lung cancer cells via induction of apoptosis. *Tropic J Pharmaceut Res.* 2019;**17**(10). <https://doi.org/10.4314/tjpr.v17i10.4>.
- Çetinkaya S. Chrysin Mediates the Induction of Apoptosis in Breast Cancer Cells via the Inhibition of the WNT/β-Catenin Signaling Pathway. *Preprint J.* 2023;**2023**. <https://doi.org/10.20944/preprints202310.0736.v1>.
- Shoieb SM, Esmat A, Khalifa AE, Abdel-Naim AB. Chrysin attenuates testosterone-induced benign prostate hyperplasia in rats. *Food Chem Toxicol.* 2018;**111**:650-9. [PubMed ID: 29247772]. <https://doi.org/10.1016/j.fct.2017.12.017>.
- Caponio GR, Cofano M, Lippolis T, Gigante I, De Nunzio V, Difonzo G, et al. Anti-Proliferative and Pro-Apoptotic Effects of Digested Aglianico Grape Pomace Extract in Human Colorectal Cancer Cells. *Molcell J.* 2022;**27**(20). [PubMed ID: 36296379]. [PubMed Central ID: PMC9611208]. <https://doi.org/10.3390/molecules27206791>.
- Khoshhravan L, Dadashpour M, Hashemi M, Zarghami N. Design and Development of Nanostructured Co Delivery of Artemisinin and Chrysin for Targeting hTERT Gene Expression in Breast Cancer Cell Line: Possible Clinical Application in Cancer Treatment. *Asian Pac J Cancer Prev.* 2022;**23**(3):919-27. [PubMed ID: 35345364]. [PubMed Central ID: PMC9360936]. <https://doi.org/10.31557/APJCP.2022.23.3.919>.
- Samarghandian S, Nezhad MA, Mohammadi G. Role of caspases, Bax and Bcl-2 in chrysin-induced apoptosis in the A549 human lung adenocarcinoma epithelial cells. *Anticancer Agents Med Chem.* 2014;**14**(6):901-9. [PubMed ID: 24521149]. <https://doi.org/10.2174/187152061466614020914402>.
- Rasouli S, Montazeri M, Mashayekhi S, Sadeghi-Soureh S, Dadashpour M, Mousazadeh H, et al. Synergistic anticancer effects of electrospun nanofiber-mediated codelivery of Curcumin and Chrysin: Possible

- application in prevention of breast cancer local recurrence. *J Drug Deliver Sci Tech.* 2020;**55**. <https://doi.org/10.1016/j.jddst.2019.101402>.
17. Pourgholi A, Dadashpour M, Mousapour A, Firouzi Amandi A, Zarghami N. Anticancer Potential of Silibinin Loaded Polymeric Nanoparticles against Breast Cancer Cells: Insight into the Apoptotic Genes Targets. *Asian Pac J Cancer Prev.* 2021;**22**(8):2587-96. [PubMed ID: 34452574]. [PubMed Central ID: PMC8629447]. <https://doi.org/10.31557/APJCP.2021.22.8.2587>.
  18. Firouzi Amandi A, Bahmanyar Z, Dadashpour M, Lak M, Natami M, Dogus Y, et al. Fabrication of magnetic niosomal platform for delivery of resveratrol: potential anticancer activity against human pancreatic cancer Capan-1 cell. *Cancer Cell Int.* 2024;**24**(1):46. [PubMed ID: 38287318]. [PubMed Central ID: PMC10826113]. <https://doi.org/10.1186/s12935-024-03219-2>.
  19. Dadashpour M, Ganjibakhsh M, Mousazadeh H, Nejati K. Increased Pro-Apoptotic and Anti-Proliferative Activities of Simvastatin Encapsulated PCL-PEG Nanoparticles on Human Breast Cancer Adenocarcinoma Cells. *J Cluster Sci.* 2022;**34**(1):211-22. <https://doi.org/10.1007/s10876-021-02217-y>.
  20. Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. *Nat Rev Clin Oncol.* 2020;**17**(7):395-417. [PubMed ID: 32203277]. [PubMed Central ID: PMC8211386]. <https://doi.org/10.1038/s41571-020-0341-y>.